Prognostic Value of CT-guided Sarcopenia for Surgical Outcomes in Esophagetomy and Total Gastrectomy Due to Neoplasia

Sponsor
Barretos Cancer Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05723783
Collaborator
(none)
80
1
24
3.3

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the degree of sarcopenia by CT and to analyze its association with morbidity and mortality after esophagectomy and / or total gastrectomy. It is also intended to analyze the association between the degree of the CT-guided sarcopenia and the nutritional status of the patients evaluated by clinical parameters, both preoperative and postoperative. Besides that, to verify the association between the degree of sarcopenia and body fat rate.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Background: Malnutrition is highly prevalent in patients with esophageal and / or stomach cancer, and is often followed by sarcopenia (loss of muscle mass and strength). Both syndromes influence negatively on prognosis of oncological patients, by increasing hospitalization time, number of complications and hospital expenses. Therefore, it is extremely important to identify patients at nutritional risk. This nutritional assessment can be done through clinical and laboratory tests, as well as can be inferred through computed tomography (CT) imaging.

    Hypothesis: To evaluate the relationship between the rate of CT-guided sarcopenia and the surgery outcomes of patients undergoing esophagectomy and / or total gastrectomy due to neoplasia.

    Methods: Prospective non-randomized study evaluating the nutritional status and morbidity and mortality of patients. The cases will be conducted according to a pre-established protocol and the sample, for convenience, will be 80 patients. Demographic data and information on diagnosis, treatment and post-surgical data will be collected, as well as anthropometric evaluation. In addition, biochemical data such as hemoglobin, transferrin and serum albumin values will be assessed to classify the patient's nutritional status. The CT images will be analyzed in order to evaluate the degree of sarcopenia and body fat rate, using the distal sections of the third lumbar vertebra. In order to evaluate skeletal muscle mass, the areas of interest will be ones between -30 and +110 hounsfield units (HU) and for the analysis of visceral fat area analysis, pixels with densities between -190 to -30 HU will be used. Both results will be converted to cm2 and analyzed through pre-set cutoff values.

    Statistical analysis: Descriptive analyzes will be performed using Fisher's exact tests, for proportions; Wilkcoxon rank-sum test for analyzes of continuous and non-parametric variables. Univariate analyzes will be performed to compare the variables of interest of the study, with the other variables. All tests will have a 5% significance level.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    80 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Prognostic Value of CT-guided Sarcopenia for Surgical Outcomes in Patients Submitted to Esophagetomy and Total Gastrectomy Due to Neoplasia
    Actual Study Start Date :
    Jan 20, 2017
    Actual Primary Completion Date :
    Dec 20, 2018
    Actual Study Completion Date :
    Jan 20, 2019

    Outcome Measures

    Primary Outcome Measures

    1. Degree of sarcopenia [Preoperative - around 30 days before surgery]

      To assess skeletal muscle mass, areas of interest were considered those between -29 to +150 Hounsfield Units (HU), and converted to cm². The final value obtained was the skeletal muscle mass index (cm²/m²) (MMI), calculated by dividing the value obtained by height (m) squared and classified according to the cut-off points established.

    2. Morbidity and mortality [Postoperative - 30 days after surgery]

      Number of complications according to the scale of clavien-dindo after esophagectomy and / or total gastrectomy

    Secondary Outcome Measures

    1. Nutritional status [Preoperative, days 30, 60 and 90 postoperative]

      Analyze the nutritional status of the patients evaluated by clinical parameters (weight in kilograms and height in meters will be combined to report Body Mass Index in kg/m²).

    2. Evolution of serum dosage of hemoglobin albumin and transferrin [Preoperative, days 30, 60 and 90 postoperative]

      Analyze biochemical parameters: serum levels of albumina (g/dL), transferrina (mg/dL) and hemoglobina (g/dL).

    3. Total, visceral and subcutaneous fat area by CT [preoperative around 30 days before surgery]

      Total fat area (TFA) and visceral fat area (VFA) were evaluated by measuring pixels with densities between -190 to -30 Hounsfield Units in cm². Subcutaneous fat area was calculated from AGT subtraction of AGT.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • elective esophagectomy and / or total gastrectomy due to neoplasia,

    • received oral or enteral diet in less than 48 hours postoperatively. For those who started with an enteral catheter, will be included in the study those with oral feedback up to 7 days.

    Exclusion Criteria:
    • Need for colonic transposition instead of gastric tube for reconstruction;

    • Presence of any adverse events related to the anesthetic act or not related to the surgical act.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Barretos Cancer Hospital Barretos São Paulo Brazil 14784400

    Sponsors and Collaborators

    • Barretos Cancer Hospital

    Investigators

    • Principal Investigator: Raphael LC Araújo, PHD, Cancer Hospital Barretos

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Barretos Cancer Hospital
    ClinicalTrials.gov Identifier:
    NCT05723783
    Other Study ID Numbers:
    • BarretosCH
    First Posted:
    Feb 13, 2023
    Last Update Posted:
    Feb 13, 2023
    Last Verified:
    Feb 1, 2023
    Keywords provided by Barretos Cancer Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 13, 2023